Multispecialty Rating of Evidence-Based Conditions for Intravenous Immunoglobulin Therapy Using a 3-Axis Prioritization Algorithm
Jordan S. Orange, MD, PhD, Matt Johnson, BA, Barbara Lennert, RN, BSN, MAOM, Katarzyna Shields, PharmD, MBA, BCOP, BCPS, Michael Eaddy, PharmD, PhD
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy
Dominic Pilon, MA, Ajay S. Behl, PhD, Lorie A. Ellis, PhD, Marie-Noëlle Robitaille, MA, Patrick Lefebvre, MA, Nancy A. Dawson, MD
Comparing Healthcare Utilization and Costs Among Medicaid-Insured Patients with Chronic Noncancer Pain with and without Opioid-Induced Constipation: A Retrospective Analysis
Tope Olufade, PhD, MPH, Amanda M. Kong, MPH, Nicole Princic, MS, Paul Juneau, MS, Rucha Kulkarni, MPH, Kui Zhang, MD, Catherine Datto, MD, MS
Chronic noncancer pain is a common and debilitating condition that affects approximately 30% of adults in the United States. The management of chronic pain is primarily aimed at relieving the pain and improving physical and emotional functions, although these are not achieved in a substantial number of patients.
The Opioid Epidemic: Healthcare Utilization and Cost Considerations
Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population
Jill R. Davis, MS, Bingcao Wu, MS, David M. Kern, PhD, Ozgur Tunceli, PhD, Kathleen M. Fox, PhD, John Horton, MS, Randall F. Legg, PharmD, MBA, Frank Trudo, MD, MBA
Chronic obstructive pulmonary disease (COPD) is characterized by declining lung function attributable to a combination of airway obstruction and inflammation.
When an Outcome Is Overdetermined: Nonadherence, Utilization, and the Impetus for Research in COPD
Steven R. Feldman, MD, PhD, Bernard Goffe, MD, Gary Rice, MBA, Matthew Mitchell, PharmD, MBA, FAMCP, Mandeep Kaur, MD, MS, Debbie Robertson, MS, RDN, LDN, Debra Sierka, PharmD, Jeffrey A. Bourret, PharmD, MS, BCPS, FASHP, Tamara S. Evans, PharmD, MPH, BCPS, Alice Gottlieb, MD, PhD
Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use
Qing Huang, PhD, MHS, Michael Grabner, PhD, Robert J. Sanchez, PhD, Vincent J. Willey, PharmD, Mark J. Cziraky, PharmD, Swetha R. Palli, MS, Thomas P. Power, MD, FACC, MRCPI
The benefits of statin therapy in reducing cardiovascular (CV) events are immense. In numerous studies, lowering low-density lipoprotein cholesterol (LDL-C) levels with statin therapy has been shown to reduce rates of major adverse CV events, such as myocardial infarction (MI) and stroke.
Using Statin Therapy to Reduce Atherosclerotic Cardiovascular Disease Risk
Rajiv Mallick, PhD, Aditya Raju, MS, BPharm, Chelsey Campbell, PharmD, MBA, Rashad Carlton, PharmD, MSPH, David Wright, MD, Kimberly Boswell, MD, Michael Eaddy, PharmD, PhD
It has been estimated that approximately 24% of adults in the United States have visible varicose veins, and an estimated 6% have evidence of more advanced chronic venous disease (eg, hyperpigmentation or healed or active ulcer).
Important Insights from Real-World Treatment Patterns and Outcomes for Varicose Veins Management
Evaluating Adherence to Dilated Eye Examination Recommendations Among Patients with Diabetes, Combined with Patient and Provider Perspectives
Maxine D. Fisher, PhD, Yamina Rajput, MS, Tao Gu, PhD, Joseph R. Singer, MD, Amanda R. Marshall, BS, Seonyoung Ryu, PharmD, John Barron, PharmD, Catherine MacLean, MD, PhD, Josephine N. Tran, PharmD, MS, Young In Park, DO, Shalin Pandya, DO, Navin John Muliyil, DO, Brandon David Jensen, DO, Kovin Huynh, DO, Quang T. Nguyen, DO, FACP, FACE, FTOS
The Centers for Disease Control and Prevention (CDC) estimates that approximately 29.1 million people in the United States have diagnosed (21 million) or undiagnosed (8.1 million) diabetes mellitus. The overall prevalence of diabetes in the US population is expected to increase as a result of growing rates of obesity and demographic shifts. Furthermore, the CDC estimates that even with a leveling of the incidence of diabetes, the prevalence of diabetes will double in the next 20 years, because of the aging US population. According to the CDC, the estimated total cost of diabetes in the United States in 2012 was $245 billion, including $176 billion for direct medical costs.
Provider and Payer Collaboration Needed to Ensure Adherence to Recommended Eye Examinations in Patients with Diabetes
Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia
Marie-Hélène Lafeuille, MA, Christian Frois, PhD, Michel Cloutier, PhD, Mei Sheng Duh, MPH, ScD, Patrick Lefebvre, MA, Jacqueline Pesa, PhD, MPH, Zoe Clancy, PharmD, John Fastenau, RPh, MPH, Mike Durkin, MSc
Schizophrenia is a devastating psychiatric disorder with a global median lifetime prevalence of 4 per 1000 and a lifetime morbidity risk of 7.2 per 1000. The treatment of schizophrenia has been focused on eliminating the symptoms of the disease and has included antipsychotic medications since the 1950s.
Patient Characteristics, Adherence, and a Metric of Organizational Performance in Behavioral Health
Treatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient Population
John Barron, PharmD, Yiqiong Xie, PhD, Sze-jung Wu, PhD, Jeff White, PharmD, Joseph R. Singer, MD, Bernard Tulsi, MSc, Alan Rosenberg, MD
Sofosbuvir was the first direct-acting antiviral drug to be approved by the US Food and Drug Administration (FDA) for the treatment of hepatitis C virus (HCV) infection. The Centers for Disease Control and Prevention estimates that between 2.7 million and 3.9 million people in the United States have chronic hepatitis C.
Evaluating the True Value of High-Cost Therapies for Hepatitis C Infection
Page 2 of 11
Results 11 - 20 of 107
Results 11 - 20 of 107